As a result, the solid tumor cohort was significantly enriched for metastatic disease and markers of poor prognosis—triple negative subtype, late presentation, and therapy resistance [8], whereas the ctDNA cohort was mainly ER+ disease. The gene discussed is ESR1; the disease is metastatic neoplasm.